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Plasma concentrationsAbstract Objective: To evaluate prospectively the appropriateness of indications, sampling time
and outcome of TDM requests at a teaching university hospital in Oman. Methods: A prospective
cross-sectional study was conducted over a four months period; October 2013–January 2014 at the
Sultan Qaboos University Hospital (SQUH), an 855 bed university teaching hospital. Appropriate-
ness criteria for indications and sampling time were deﬁned a priori. The evaluated drug’s requests
were for carbamazepine, phenytoin, phenobarbital, valproic acid, digoxin, gentamicin, amikacin,
vancomycin, tobramycin, theophylline, lithium, and cyclosporine. Results: Of 733 evaluated
TDM requisitions, the majority were for antibiotics (75.0%) followed by antiepileptics (10.5%)
and cyclosporine (8.9%). Most of the requests had appropriate indication (78.2%), however, only
28.5% had appropriate sampling time. Results were applied by dosage adjustments in 65.8% of
requests and some of the inappropriately sampled requests (15.3%) were used as a basis for mod-
ifying the dosage regimen. Of all the reported plasma concentrations 42.3%, 41.2%, and 16.5%
were within, below and above the reference range, respectively. Conclusion: TDM service is much
less than optimal in SQUH. A lot of effort needs to be carried out to improve TDM use in the devel-
oping countries as adjusting the doses on results that are based on wrong sampling time might
expose patients to toxicity or therapeutic failure.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Therapeutic drug monitoring (TDM) is an established useful
clinical service in pharmacotherapy. It helps in identifying
alternations in drug disposition, adjusting drugs’ dosage regi-
men and minimizing adverse effects (Doogue and Martin,
2010; Eliasson et al., 2013; Mehler-Wex et al., 2009). It is
widely applied to a variety of drug classes such as antibiotics,
Table 1 Patient’s demographic and laboratory data.
N (%) Mean ± SD (range)/median (IQR)
Age (years) 733 (100) 25.38 ± 26.8 (0–85)
Neonates 119 (16.2)
Infants 106 (14.5)
Children and Adolescence 150 (20.5)
Adults 358 (48.8)
Gender M 395 (53.9)
F 338 (46.1)
Ordering units Medical 370 (50.5)
Hematology 114 (30.8)
General 91 (24.6)
Others 109 (44.6)
Pediatric 236 (32.2)
Neonatal 98 (41.5)
Hematology 76 (32.2)
General 36 (15.3)
Others 26 (11.0)
Surgical 75 (10.2)
Pediatric 29 (38.7)
Cardio-thoracic 21(28.0)
General 18 (24.0)
Others 7 (9.3)
Others 52 (7.1)
Weight (Kg) 39.92 ± 31.56 (0.67–150)
Sampling time and indications appropriateness of therapeutically monitored drugs 459antiepileptics, immunosuppressant and others (Eliasson et al.,
2013; Kang and Lee, 2009). Several studies found that inap-
propriate utilization of TDM such as inappropriateness in
indications, sampling time and application of results, might
lead to a signiﬁcant waste of resources especially for develop-
ing countries (Norris et al., 2010; Ostad Haji et al., 2013;
Nilsson et al., 2001; Ab Rahman et al., 2013; Ratanajamit
et al., 2009; Dalaklioglu, 2013). In Oman, TDM use is limited
for tertiary care hospitals, which are few. Among these is the
Sultan Qaboos University Hospital (SQUH), a university
teaching hospital, were TDM was introduced almost 15 years
ago. In 2012 the total number of TDM requests was 6558.
These were carried for the following drugs: carbamazepine,
phenytoin, valproic acid, digoxin, phenobarbital, gentamicin,
tobramycin, amikacin, vancomycin, theophylline, lithium,
cyclosporine, and methotrexate. Two retrospective studies at
SQUH one on antiepileptic drugs (AEDs) and the other on
vancomycin, have been conducted. The evaluated AEDs
TDM requests (354) showed that 50%, 37% and 13% of all
reported concentrations were either below, within or above
the therapeutic range, respectively (Al Za’abi et al., 2013a).
Similarly the vancomycin study showed that 70.2% and
7.6% of the samples were either below or above the recom-
mended range, respectively (Al Za’abi et al., 2013b). Despite
the availability of this service there was no study documenting
the appropriateness of sampling time and indications of these
requests. Therefore the present study was performed to pro-
spectively assess the appropriateness of indications, sampling
time and outcome of TDM requests at SQUH.
2. Materials and methods
The study was a prospective, cross-sectional type. It was con-
ducted over a four month period; October 2013 to January2014 at SQUH, an 855 bed university teaching hospital. It
included all TDM requests for inpatients. Patients were identi-
ﬁed using TDM requests reaching the biochemistry laboratory
where the measurements for drugs are usually carried out, and
retrieved using the hospital information system program
‘‘Trackcare’’. A data collection sheet was created to collect
the required information. It contained information regarding
demographic data such as sex and age, request data such as
unit, time, indications and results outcome. The drugs’ concen-
trations were measured by an automated analyzer Roche n
Hitachi Cobas systems.
Appropriateness criteria for indications and sampling time
were deﬁned a priori based on the literature and SQUH avail-
able TDM guidelines and the study was approved by the Sul-
tan Qaboos University Medical Ethics Committee before
commencing data collection.
Data are presented as frequencies and percentages and as
mean and median where appropriate. Chi square test was used
to explore the assassination between sex, age, nursing duties
shifts, or ordering units and sampling time or indications
appropriateness. A p values <0.05 were considered statisti-
cally signiﬁcant.
3. Results
A total of 733 TDM requests during the four month collection
period (October 2013–January 2014) that fulﬁlled the inclu-
sions criteria were recruited and evaluated. Almost half of
the requests (n= 395, 53.9%) were for males. Most of the
patients were less than 18 years of age (n= 385, 52.5%) with
a mean age and weight of 25.38 ± 26.8 years,
39.92 ± 31.56 kg, respectively.
Antibiotics were the most frequently (n= 550, 75%) mon-
itored drugs in all age groups; 94.9%, 62.3, 65.0%, and 76.7%
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460 M. Al Za’abi et al.in neonates, infants, children and adults, respectively followed
by AEDs (n= 77, 10.5%) and cyclosporine (n= 65, 8.9%).
The majority of the requests were ordered by medical units
(n= 370, 50.5%) followed by pediatric units (n= 236,
32.2%) and surgical units (n= 75, 10.2%). Table 1 illustrates
the patient’s demographic and laboratory data while Table 2
illustrates the monitored drugs.
TDM plasma concentration results were compared with the
reference range of each drug and classiﬁed into low, within,
and high. Among all the requests, 310 (42.3%) were within
the range, 302 (41.0%) were lower than the range, and 121
(16.5%) were higher than the range.
Most of the requests had appropriate indications (n= 573,
78.2%). Majority of these were indicated as initial monitoring
for the dosage regimen (n= 347, 60.5%) followed by a change
in dosage (n= 84, 14.7%). Most of the inappropriate indica-
tions (n= 82, 51.3%) were for pre levels of a once daily dosing
regimen of amikacin and/or gentamicin followed by orders
where TDM is not needed (n= 50, 31.3%). Inappropriate indi-
cations were higher among patients <18 years than patients
>18 years (23.9% v. 17.8%; p= 0.048). Furthermore, inap-
propriate indications was statistically higher in pediatric units
(28.0%) than medical (18.7%) or surgical (9.3%) ones
(p= 0.001) (Table 3).
Sampling time was found to be appropriate in only 28.5%
(n= 209) of requests. Most of inappropriateness (n= 468,
63.8%) was due to wrong sampling time (n= 409, 55.8%)
or did not reach the study state concentrations (n= 59,
8%). In 7.6% (n= 56) of requests the sampling times were
not clear. Inappropriateness was more in patients <18 years
of age (73.6% v. 64.2%; p= 0.008) and with more requests
from surgical units than pediatrics or medical units (82.2%,
75.7% and 59.9%; respectively, p= 0.001). There was no sig-
niﬁcant statistical association between the sampling time
appropriateness and sex or different nursing duty shifts.
The results of TDM requests were mostly applied (n= 482,
65.8%) by adjusting the dosage regimen as required. Among
these, 50.0% (n= 280) required no change, in 16.1%
(n= 77) doses were increased and in 9.8% (n= 47) doses
were reduced or stopped/withhold. Only a quarter (n= 178,
24.3%) had inappropriate application where a required change
did not occur. In 50 and 62 of requests (15.3%) the dosage reg-
imens were increased and reduced, respectively, based on inap-
propriate sampling time results.4. Discussion
TDM is an important service that helps in improving dose
individualization, assessing compliance and reducing toxicity.
Thus there is an increase in demand for this service which lead
to an increase in hospital cost and gauges for more resources
(Eliasson et al., 2013; Westin et al., 2012). For the developing
countries where there is a paucity of resources, appropriate uti-
lization of TDM is of paramount importance with other ser-
vices. The result of this audit showed that there is
considerable work is needed to be done in order to improve
this service in our setting. Among these is the substantial per-
centage (71.5%) of inappropriate sampling time. These results
are somehow comparable to the rest of the developing coun-
tries. Due to the nature of drugs undergoing TDM, it is imper-
ative to emphasis the importance of sampling time as correct
Table 3 Association of indications and sampling time appropriateness with patients’ characteristics, nursing duty shifts, and ordering
units.
Variable Sampling time appropriateness Indication appropriateness
Appropriate n (%) Inappropriate n (%) p Appropriate n (%) Inappropriate n (%) p
Gender
 Male 104 (28.8) 257 (71.2) 0.237 317 (80.3) 78 (19.7) 0.417
 Female 104 (33.0) 211 (67.0) 263 (77.8) 75 (22.2)
Age (years)
 <18 95 (26.4) 265 (73.6) 0.008 284 (76.1) 89 (23.9) 0.048
 >=18 113 (35.8) 203 (64.2) 296 (82.2) 64 (17.8)
Nursing duty shifts (time)
 07:30–14:00 63 (29.9) 148 (70.1) 0.117 – – –
 14:00–21:30 67 (36.6) 116 (63.4) – –
 21:30–7:30 78 (27.7) 204 (72.3) – –
Ordering units
 Medical 115 (40.1) 172 (59.9) 0.000 266 (81.3) 61 (18.7) 0.001
 Pediatrics 65 (24.3) 203 (75.7) 201 (72.0) 78 (28.0)
 Surgical 13 (17.8) 60 (82.2) 68 (90.7) 7 (9.3)
 Others 15 (31.3) 33 (68.8) 45 (86.5) 7 (13.5)
Sampling time and indications appropriateness of therapeutically monitored drugs 461interpretation of TDM results very much depends on the infor-
mation on sampling time and duration of therapy. Adjusting
the doses on results that are based on wrong sampling time
might expose patients to toxicity or therapeutic failure.
Digoxin, for example, in this study and other studies in the
developed countries was sampled before it reaches the steady
state (Sidwell et al., 2003; Mordasini et al., 2002). This might
lead to unnecessary higher or lower than appropriate
therapeutic dosage regimen.
The aminoglycoside antibiotics gentamicin and amikacin
and vancomycin were the major drugs (75.0%) to be moni-
tored in this study perhaps due to the inclusion of inpatients
only. Therefore, these antibiotics represent most of the TDM
cost. It was also found that most of the inappropriate sampling
time (51.3%) was for these antibiotics. The results of these
samples were considered in the dosage regimen in some
patients. This might increase the chance for emergences of
resistant infections which in turn might affect treated patients
and may be the community at large.
Plasma concentration results in our study showed that 310
of requests (42.3%) were within the therapeutic ranges requir-
ing no change in the dosage regimen. Another 302 requests
(41.2%) had low plasma concentrations that might require
an increase in the dosage regimen and therefore the dose was
increased in 73 (24.2%) of them. There were 121 requests
(16.5%) with high plasma concentrations where reducing,
stopping, or withholding of the dosage regimen occurred in
93 (76.9%) of them. This shows that dosage regimens were
changed more frequently with toxic plasma concentrations
than with sub therapeutic concentrations. It seems that
physicians are more concerned about toxic results than
sub-therapeutic concentrations. Although this sometimes
might be related the patients’ clinical status, however, sub-
therapeutic concentrations may lead to the failure of therapy
and development of resistance to some drugs like antibiotics
and might also lead to increased length of hospitalization
and health care costs. This trend has also been observed else-
where (Ratanajamit et al., 2009; Dalaklioglu, 2013; Taur
et al., 2013). Sub-therapeutic concentrations should be asclinically alarming as toxic concentrations as failure of therapy
and appearance of toxicity should be considered equally.
There was no signiﬁcant statistical association between the
sampling time appropriateness and different nurses’ duty
shifts. This might suggest that different working time has no
effect on sampling time appropriateness but rather, it might
be the lack of knowledge about sampling time. Statistically it
was also shown that more inappropriate sampling times
occurred among patients younger than 18 years and more
among orders requested from surgical units. There are no clear
reasons why this might be the case.
As with all studies we could identify some limitations. For
example, the assessment of indications was retrieved from
TDM requests for which we cannot assure that the supplied
information was complete or correct. It also should be taken
into account that the dose adjustments should never be made
on the basis of serum drug concentrations alone but should
be justiﬁed after careful assessment of the patient’s clinical sta-
tus. Finally, the impact of changing the dosage regimen based
on the interpretation of results with inappropriate sampling
time on the patient and health care system could not be
measured.
5. Conclusion
This audit identiﬁed several issues that need to be undertaken
in order to optimize TDM in our setting. It also raises several
points such as the need of increasing the involvement of phar-
macists in TDM service as their presence during clinical
rounds has been shown to reduce inappropriateness and mon-
itoring costs (Ratanajamit et al., 2009). It also raises the query
to policy makers to decide whether it is more economically
favorable to consolidate resources in the pharmacy department
and biochemistry department than current practice.Declaration of interest
None.
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